Table 4.
Clinical characteristics for the 20 families affected with INF2-related disease.
Family ID | Self-reported Ethnicity/Country | Ages at disease onset | Number affected | Ages at ESRD | Number with ESRD | Histology | Number with Biopsy |
---|---|---|---|---|---|---|---|
FG-BR | European ancestry/Canada | 12–67 | 19 | 32–67 | 6 | FSGS | 7 |
FG-DM | European ancestry/Ireland and USA | 13–18 | 2 | 21–29 | 2 | FSGS | 2 |
FG-EA | African American/USA | 27–33 | 3 | 30–40 | 2 | FSGS | 1 |
FG-EF | European ancestry/USA | 19–35 | 5 | 49 | 1 | FSGS | 3 |
FG-EP | European ancestry/USA | 11–13 | 3 | 13–14 | 3 | FSGS | 3 |
FG-ER | European ancestry/Canada | 13–60 | 9 | 20–50 | 6 | Unclear | 3 |
FG-FG | European ancestry/USA | 12–72 | 7 | 17–60 | 3 | FSGS | 3 |
FG-GY | African American/USA | 17–30 | 8 | 17–30 | 7 | FSGS | 2 |
FG-HT | European ancestry/USA | 13–29 | 9 | 21–22 | 9 | FSGS | 4 |
FG-JN | European ancestry/USA | 22–45 | 10 | 30–45 | 4 | FSGS | At least 1 |
FG-JY | European ancestry/Australia | 21-? | 2 | 35 | 1 | FSGS | 3 |
FG-KM | European ancestry/Poland | 15–24 | 4 | 25–44 | 2 | FSGS | 2 |
FG-KQ | Asian/USA | ? | 2 | 26-? | 2 | FSGS | 1 |
FG-LL | European ancestry | 19 | 2 | 19 | 1 | FSGS | At least 1 |
FG-LP | European ancestry/USA | 17–27 | 4 | 25–28 | 3 | FSGS | 1 |
FG-LW | European ancestry | 22–30 | 4 | 27–30 | 3 | FSGS | 1 |
FG-LY | European ancestry/France | 18 | 4 | 33 | 3 | FSGS | 1 |
FG-ME | European ancestry | 15–16 | 3 | - | 0 | FSGS | 1 |
FS-B | European ancestry/USA | 13–21 | 5 | 23–30 | 4 | FSGS | 3 |
FS-V | European ancestry/Sweden and Denmark | 15 | 6 | 30 | 2 | FSGS | 1 |